Compare DexCom, Inc. (DXCM) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Shell PLC — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Shell PLC trades at $100.18 (market cap $284.34B). The key difference: Shell PLC is far larger — about 8.9× DexCom, Inc.'s market cap, and Shell PLC pays a 3.12% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Shell PLC for 90 Days on average.
| DXCM | SHEL | |
|---|---|---|
Market Cap | $31.86B | $284.34B |
Volume | 3,607,070 | 9,097,469 |
Sector | Health | Energy |
52-Week High | $92.34 | $100.20 |
52-Week Low | $54.84 | $70.31 |
Typical Hold Time | 62 Days | 90 Days |
Enterprise Value | $31.32B | $326.04B |
Dividend Yield | — | 3.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
Shell (SHEL) trades at $100.20, up 3.46% today, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and positive earnings surprises in recent quarters. Recent developments include the approval of LNG Canada Phase 2 expansion, doubling export capacity, and strategic portfolio optimization through asset sales. Financial metrics indicate solid profitability with 8.76% net income margin and attractive valuation at P/E of 11.08.
Shell presents a compelling investment case with strong LNG growth prospects and portfolio optimization driving future cash flows. However, declining revenue trends from $381.3B in 2022 to $266.9B in 2025 and volatile energy prices pose execution risks. Analyst consensus remains bullish with $102.53 price target, though current RSI levels suggest potential near-term overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
